Fate Therapeutics CEO Valamehr Bahram Sells 43,947 Shares

What Happened
Valamehr Bahram, President & CEO and a director of Fate Therapeutics (FATE), disposed of 43,947 shares on 2026-08-04 in an open-market/private sale for total proceeds of $108,101. The sales were executed to satisfy tax withholding obligations tied to the vesting of 75,000 RSUs granted on July 29, 2024, and were automatic "sell-to-cover" transactions rather than discretionary sales.

Key Details

• Transaction date: 2026-08-04; Form 4 filed 2026-08-05 (appears timely).
• Shares sold: 43,947; weighted average sale price range: $2.415–$2.540; total proceeds reported: $108,101.
• Reason: Tax withholding on vesting of 75,000 RSUs (automatic sell-to-cover per footnote).
• Footnotes: F1 confirms sales were automatic to cover taxes; F2 provides the price range and notes more detailed price breakdown is available on request.
• Post-transaction holdings: Not specified in the provided excerpt of the filing.

Context
This was a routine sell-to-cover to satisfy tax withholding after RSU vesting (code F in many filings). Such transactions are administrative and do not necessarily indicate a change in insider sentiment or a discretionary sale.